Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled oral mannitol dose-escalation study in Parkinson's disease
MOH_2018-01-16_002029Phase 2Recruiting
- Sponsor
- ד"ר דוד ארקדיר
- Start
- Dec 2017
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Bronchitol in Parkinson's disease (PD), sponsored by ד"ר דוד ארקדיר. Primary endpoints: Safety and tolerability and Optimal dose identification. Started Dec 2017; status: recruiting.
02
Drugs
Bronchitol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2018-01-16_002029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-16_002029.